Brief: Epigenomics Gets Ce-Ivd Mark For Lung Cancer Test Epi Prolung
19/12/2017 07:45
Dec 19 (Reuters) - EPIGENOMICS AG ECXn.DE :
* DGAP-NEWS: EPIGENOMICS AG GETS CE-IVD MARK FOR LUNG CANCER
TEST
EPI PROLUNG(R)
Source text for Eikon: ID:nEQ5BFshxa
Further company coverage: ECXn.DE
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Epigenomics AG
See all newsU.S. FDA advisers back approval for Guardant's blood-based cancer test (updated)
U.S. FDA advisers back approval for Guardant's cancer test
Brief: Epigenomics Says Closing Of Agreement On The Acquisition Of Almost All Assets And Adjustment Of Guidance For 2023
Brief: Epigenomics AG Says It Entered Into Agreement On The Acquisition Of Almost All Assets With New Day Diagnostics LLC
Brief: Epigenomics Says Chief Scientific Officer Andrew Lukowiak Resigns